Takayasu arteritis.
Journal
Current opinion in rheumatology
ISSN: 1531-6963
Titre abrégé: Curr Opin Rheumatol
Pays: United States
ID NLM: 9000851
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
27
10
2021
medline:
1
2
2022
entrez:
26
10
2021
Statut:
ppublish
Résumé
The purpose of this review is to summarize the recent advances in Takayasu arteritis (TAK), mainly focusing on pathogenesis, imaging modalities, and management. Three novel clusters based on angiographic findings were identified in the Indian cohort and replicated in the North American cohorts. Different new imaging modalities have been tried in the assessment of arterial inflammation with promising results. There is more evidence on the long-term use of tocilizumab, but relapses are common. In light of the recent findings on the pathogenesis of TAK, Janus kinase inhibitors seem to be promising. Improvement in imaging modalities and in our understanding of the disease pathogenesis will allow us to better assess the disease activity and identify effective therapeutic agents.
Identifiants
pubmed: 34698679
doi: 10.1097/BOR.0000000000000852
pii: 00002281-202201000-00005
doi:
Substances chimiques
Janus Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
18-24Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Seyahi E. Takayasu arteritis: an update. Curr Opin Rheumatol 2017; 29:51–56.
Rutter M, Bowley J, Lanyon PC, et al. A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. Rheumatology (Oxford) 2021; keab406doi: 10.1093/rheumatology/keab406. [Epub ahead of print].
doi: 10.1093/rheumatology/keab406.
Zhang Z, Wang W, Zhou M, et al. An observational study of sex differences in Takayasu arteritis in China: implications for worldwide regional differences. Ann Vasc Surg 2020; 66:309–317.
Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79:19–30.
Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol 2021; 73:1349–1365.
Ortiz-Fernandez L, Saruhan-Direskeneli G, Alibaz-Oner F, et al. Identification of susceptibility loci for Takayasu arteritis through a large multiancestral genome-wide association study. Am J Hum Genet 2021; 108:84–99.
Esatoglu SN, Ok AM, Ucar D, et al. Takayasu's arteritis: associated inflammatory diseases. Clin Exp Rheumatol 2020; 38 Suppl 124:61–68.
Eshed I, Druyan A, Stern M, et al. The prevalence of sacroiliitis on abdominal MRI examinations of patients with Takayasu arteritis. Acta Radiol 2021; 284185121996270doi: 10.1177/0284185121996270. [Epub ahead of print].
doi: 10.1177/0284185121996270.
Goel R, Gribbons KB, Carette S, et al. Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. Rheumatology (Oxford) 2020; 59:1118–1127.
Wen X, Song G, Hu C, et al. Identification of novel serological autoantibodies in Takayasu arteritis patients using HuProt arrays. Mol Cell Proteomics 2021; 20:100036.
Mutoh T, Shirai T, Ishii T, et al. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nat Commun 2020; 11:1253.
Svensson C, Eriksson P, Zachrisson H. Vascular ultrasound for monitoring of inflammatory activity in Takayasu arteritis. Clin Physiol Funct Imaging 2020; 40:37–45.
Germano G, Macchioni P, Possemato N, et al. Contrast-enhanced ultrasound of the carotid artery in patients with large vessel vasculitis: correlation with positron emission tomography findings. Arthritis Care Res (Hoboken) 2017; 69:143–149.
Wang Y, Wang YH, Tian XP, et al. Contrast-enhanced ultrasound for evaluating arteritis activity in Takayasu arteritis patients. Clin Rheumatol 2020; 39:1229–1235.
Sato W, Suto Y, Yamanaka T, Watanabe H. An advanced ultrasound application used to assess peripheral vascular diseases: superb microvascular imaging. J Echocardiogr 2021; 19:150–157.
Sato W, Sato T, Iino T, et al. Visualization of arterial wall vascularization using superb microvascular imaging in active-stage Takayasu arteritis. Eur Heart J Cardiovasc Imaging 2019; 20:719.
Ito S, Tahara N, Hirakata S, et al. Signal intensity of superb micro-vascular imaging associates with the activity of vascular inflammation in Takayasu arteritis. J Nucl Cardiol 2020; 27:1063–1065.
Mattay RR, Saucedo JF, Lehman VT, et al. Current clinical applications of intracranial vessel wall MR imaging. Semin Ultrasound CT MR 2021; 42:463–473.
Song JW, Obusez EC, Raymond SB, et al. Vessel wall MRI added to MR angiography in the evaluation of suspected vasculopathies. J Neuroimaging 2019; 29:454–457.
Kono M, Shimizu Y. Vessel wall magnetic resonance imaging of Takayasu arteritis. Circ Rep 2021; 3:354–355.
Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018; 77:636–643.
Yang H, Lv P, Zhang R, et al. Detection of mural inflammation with low b-value diffusion-weighted imaging in patients with active Takayasu Arteritis. Eur Radiol 2021; 31:6666–6675.
Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994; 120:919–929.
Misra R, Danda D, Rajappa SM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013; 52:1795–1801.
Ma LY, Wu B, Jin XJ, et al. A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study. Rheumatology (Oxford) 2021; keab487doi: 10.1093/rheumatology/keab487. [Epub ahead of print].
doi: 10.1093/rheumatology/keab487.
Slart RHJA. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 2018; 45:1250–1269.
Dashora HR, Rosenblum JS, Quinn KA, et al. Comparing semi-quantitative and qualitative methods of vascular FDG-PET activity measurement in large-vessel vasculitis. J Nucl Med 2021; jnumed.121.262326. doi: 10.2967/jnumed.121.262326. [Epub ahead of print].
doi: 10.2967/jnumed.121.262326.
Kang F, Han Q, Zhou X, et al. Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu's arteritis patients. Eur J Nucl Med Mol Imaging 2020; 47:3107–3117.
Bucerius J, Hyafil F, Verberne HJ, et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging 2016; 43:780–792.
Quinn KA, Rosenblum JS, Rimland CA, et al. Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis. Semin Arthritis Rheum 2020; 50:71–76.
Li G, Liu F, Wang Y, et al. Effects of resistance exercise on treatment outcome and laboratory parameters of Takayasu arteritis with magnetic resonance imaging diagnosis: a randomized parallel controlled clinical trial. Clin Cardiol 2020; 43:1273–1278.
Astley C, Clemente G, Terreri MT, et al. Home-based exercise training in childhood-onset Takayasu arteritis: a multicenter, randomized, controlled trial. Front Immunol 2021; 12:705250.
De Souza AW, Da Silva MD, Machado LS, et al. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012; 41:227–230.
De Souza AW, De Almeida Agustinelli R, De Cinque Almeida H, et al. Leflunomide in Takayasu arteritis - a long term observational study. Rev Bras Reumatol 2016; 56:371–375.
Ying S, Xiaomeng C, Xiaomin D, et al. Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Ther Adv Musculoskelet Dis 2020; 12:1759720X20930114.
Dai X, Cui X, Sun Y, et al. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study. Ther Adv Chronic Dis 2020; 11:2040622320922019.
Wu C, Sun Y, Cui X, et al. Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. T Ther Adv Chronic Dis 2020; 11:2040622320975233.
Dos Santos JP, Artigiani Neto R, Mangueira CLP, et al. Associations between clinical features and therapy with macrophage subpopulations and T cells in inflammatory lesions in the aorta from patients with Takayasu arteritis. Clin Exp Immunol 2020; 202:384–393.
Kong X, Xu M, Cui X, et al. Potential role of macrophage phenotypes and CCL2 in the pathogenesis of Takayasu arteritis. Front Immunol 2021; 12:646516.
Kayhan S, Guzel A, Duran L, et al. Effects of leflunomide on inflamation and fibrosis in bleomycine induced pulmonary fibrosis in wistar albino rats. J Thorac Dis 2013; 5:641–649.
Ma ZG, Zhang X, Yuan YP, et al. A77 1726 (leflunomide) blocks and reverses cardiac hypertrophy and fibrosis in mice. Clin Sci (Lond) 2018; 132:685–699.
Yao HW, Li J, Chen JQ, Xu SY. Inhibitory effect of leflunomide on hepatic fibrosis induced by CCl4 in rats. Acta Pharmacol Sin 2004; 25:915–920.
Cui X, Kong X, Chen R, et al. The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis. Clin Exp Rheumatol 2020; 38 Suppl 124:69–78.
Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford) 2020; 59:2427–2434.
Wu S, Kong X, Cui X, et al. Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population. Joint Bone Spine 2021; 88:105186.
Mekinian A, Saadoun D, Vicaut E, et al. Tocilizumab in treatment-naive patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther 2020; 22:218.
Kong X, Sun Y, Dai X, et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis 2021; annrheumdis-2021-220832. doi: 10.1136/annrheumdis-2021-220832. [Epub ahead of print].
doi: 10.1136/annrheumdis-2021-220832.
Regnier P, Le Joncour A, Maciejewski-Duval A, et al. Targeting JAK/STAT pathway in Takayasu's arteritis. Ann Rheum Dis 2020; 79:951–959.
Desbois AC, Regnier P, Quiniou V, et al. Specific follicular helper T cell signature in Takayasu arteritis. Arthritis Rheumatol 2021; 73:1233–1243.